The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
Ichnos will receive an upfront payment of Euro 20.8 million as well as additional development and commercial milestone payments and tiered royalties based upon future global sales
The company has received five final approvals
Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients
Glenmark Pharmaceuticals announced its financial results for the fourth quarter ended March 31, 2022
Subscribe To Our Newsletter & Stay Updated
